Nirsevimab Immunization Outcomes in the First Two Years
Nirsevimab, a long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV), was associated with a substantial reduction ...
Nirsevimab, a long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV), was associated with a substantial reduction ...
In a groundbreaking study, researchers have examined the critical role of early intravenous immunoglobulin (IVIG) administration in improving outcomes for ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine